

Attorney Docket No.: DEX-0209
Inventors: Salceda et al.
Serial No.: 09/886,241
Filing Date: June 21, 2001
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claims 1-2 (canceled)

Claim 3 (currently amended): A method for diagnosing the presence of breast cancer in a patient comprising:

(a) determining levels of a breast specific gene (BSG) of ~~claim 1~~ in cells, tissues or bodily fluids in a patient; and

(b) comparing the determined levels of BSG with levels of BSG in cells, tissues or bodily fluids from a normal human control, wherein a change in determined levels of BSG in said patient versus normal human control is associated with the presence of breast cancer, wherein the BSG comprises a polynucleotide of SEQ ID NO:4, a polynucleotide encoding the same polypeptide as encoded by SEQ ID NO:4 or a protein encoded thereby.

Claim 4 (currently amended): A method of diagnosing metastases of breast cancer in a patient comprising:

(a) identifying a patient having breast cancer that is not known to have metastasized;

(b) determining levels of a breast specific gene (BSG) of ~~claim 1~~ in a sample of cells, tissues, or bodily fluid from said

Attorney Docket No.: DEX-0209
Inventors: Salceda et al.
Serial No.: 09/886,241
Filing Date: June 21, 2001
Page 4

patient; and

(c) comparing the determined BSG levels with levels of BSG in cells, tissue, or bodily fluid of a normal human control, wherein an increase in determined BSG levels in the patient versus the normal human control is associated with a cancer which has metastasized, wherein the BSG comprises a polynucleotide of SEQ ID NO:4, a polynucleotide encoding the same polypeptide as encoded by SEQ ID NO:4 or a protein encoded thereby.

Claim 5 (currently amended): A method of staging breast cancer in a patient having breast cancer comprising:

AM
(a) identifying a patient having breast cancer;
(b) determining levels of a breast specific gene (BSG) of ~~claim 1~~ in a sample of cells, tissue, or bodily fluid from said patient; and

(c) comparing determined BSG levels with levels of BSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in determined BSG levels in said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the determined BSG levels is associated with a cancer which is regressing or in remission, wherein the BSG comprises a polynucleotide of SEQ ID NO:4, a polynucleotide encoding the same polypeptide as encoded by SEQ ID

Attorney Docket No.: DEX-0209
Inventors: Salceda et al.
Serial No.: 09/886,241
Filing Date: June 21, 2001
Page 5

NO:4 or a protein encoded thereby.

Claim 6 (currently amended): A method of monitoring breast cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having breast cancer that is not known to have metastasized;

(b) periodically determining levels of a breast specific gene (BSG) of claim 1 in samples of cells, tissues, or bodily fluid from said patient; and

AI
(c) comparing the periodically determined BSG levels with levels of BSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically determined BSG levels in the patient versus the normal human control is associated with a cancer which has metastasized, wherein the BSG comprises a polynucleotide of SEO ID NO:4, a polynucleotide encoding the same polypeptide as encoded by SEO ID NO:4 or a protein encoded thereby.

Claim 7 (currently amended): A method of monitoring a change in stage of breast cancer in a patient comprising:

(a) identifying a patient having breast cancer;

(b) periodically determining levels of a breast specific gene (BSG) of claim 1 in cells, tissues, or bodily fluid from said patient; and

Attorney Docket No.: DEX-0209
Inventors: Salceda et al.
Serial No.: 09/886,241
Filing Date: June 21, 2001
Page 6

AI
(c) comparing the periodically determined BSG levels with levels of BSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically determined BSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission, wherein the BSG comprises a polynucleotide of SEQ ID NO:4, a polynucleotide encoding the same polypeptide as encoded by SEQ ID NO:4 or a protein encoded thereby.

Claims 8-15 (canceled)
